The global particle therapy market is expected to be driven by rise in prevalence of cancer, low risk of treatment-induced disorders, and increase in the number of particle therapy centers across the world. The primary goal of the proton therapy is to improve radiation therapy by using proton beams for the treatment of localized tumors and radiosurgery. Particle therapy is a type of radiotherapy.

Download PDF Brochure @ https://www.marketsandmarkets.com/pdfdownloadNew.asp?id=12809137

Particle Therapy Market

Market growth is driven by factors such as growing adoption of particle therapy in clinical trials and the increasing number of particle therapy centers worldwide. Emerging markets are China India, Brazil, and South Africa are showing lucrative growth opportunities to market.

The particle therapy market is projected to reach USD 1,004 million by 2027 from USD 677 million in 2022, growing at a CAGR of 8.2% from 2022 to 2027.

“Pediatric cancer defined for the largest share in the particle therapy market by cancer type”

Based on cancer type, the particle therapy market is segmented into prostate cancer. pediatric cancer, lung cancer, breast cancer, head & neck cancer, and other cancers. The pediatric cancer segment is holds the largest share of 24.8% of the particle therapy market in 2021 with CAGR of 10.4% during the forecast period. The growing incidence of pediatric cancer alongside the high success rates is the major factors driving the growth of this market segment.

Access full Research Insights @ https://www.marketsandmarkets.com/Market-Reports/particle-therapy-market-12809137.html

“Products such as cyclotron accounted for the largest share in the particle therapy market by product type”

Based on products & services, the particle therapy market is segmented into products and services. In 2021, products are estimated to account for the largest share of 78.6% of the particle therapy market. The increasing incidence of cancer cases is the major factor responsible for the growth of this segment.

“Based on system, multi-room systems holds the largest share in the particle therapy”

Based on the system, the particle therapy market is segmented into single-room and multi-room particle therapy systems. The multi-room systems segment is expected to account for the largest share (67.8%) of the particle therapy market. The large share of this segment can be attributed to the growing availability of these systems and their lower shielding requirements as compared to single-room systems.

Key Market Players :

Prominent players in the particle therapy market include IBA Worldwide (EU), Mevion Medical Systems (US), Varian Medical Systems, Inc. (US), Sumitomo Heavy Industries, Ltd. (Japan), Hitachi, Ltd. (Japan), Toshiba Medical Systems Corporation (Japan), and Provision Healthcare, LLC (US). These players have implemented various development strategies such as product launches, acquisition, and expansion to other geography.

IBA Worldwide (EU)

IBA is one of the leading players in the particle therapy market. Its Proton Therapy segment offers Proteus PLUS, a treatment room solution, and Proteus ONE, a single-room cancer treatment solution. IBA caters its products to various end users, including hospitals and ambulatory radiotherapy centers. The firm focuses on strengthening its market position by adopting both organic (such as product development and approvals) as well as inorganic growth strategies (such as agreements, collaborations, and partnerships). During the last three years, the company has significantly invested in R&D activities.

The research report categorizes particle therapy market into the following segments and sub-segments:

By Type

Proton Therapy
Heavy Ion Therapy
By Product & Service

Products
Cyclotrons
Synchrotrons
Synchrocyclotrons
Services
By System

Multi-Room Systems
Single-Room Systems
By Cancer Type

Pediatric Cancer
Prostate Cancer
Lung Cancer
Breast Cancer
Head and Neck Cancer
Other Cancers
By Application

By App Treatment Applications
Research Applications
By Region

North America
US
Canada
Europe
Germany
France
UK
Italy
Spain
Rest of europe
Asia pacific
Japan
China
India
Rest of Asia Pacific
Latin america
Middle east & africa
Recent Developments:

In January 2019, Varian Medical Systems, Inc. (US) partnership with Oncora Medical (US). This investment partnership was aimed at accelerating the development of software tools to enable precision medicine in radiation oncology.
In April 2021 2021, IBA Worldwide (EU) partnership with Tractebel (US). This partnership agreement to support IBA’s customers with their proton therapy design and construction projects.
Make an Enquire to Buy this Report @ https://www.marketsandmarkets.com/Enquiry_Before_BuyingNew.asp?id=12809137

Frequently Asked Questions (FAQ):

Which are the top industry players in the particle therapy market?
What are the top trends in the particle therapy market?
Which region is dominating in the particle therapy market?